The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study.

Paul W Blair, Diane M Brown, Minyoung Jang, Annukka A R Antar, Jeanne C Keruly, Vismaya S Bachu, Jennifer L Townsend, Jeffrey A Tornheim, Sara C Keller, Lauren Sauer, David L Thomas, Yukari C Manabe, Ambulatory COVID Study Team
Author Information
  1. Paul W Blair: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. ORCID
  2. Diane M Brown: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  3. Minyoung Jang: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  4. Annukka A R Antar: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  5. Jeanne C Keruly: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  6. Vismaya S Bachu: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  7. Jennifer L Townsend: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  8. Jeffrey A Tornheim: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  9. Sara C Keller: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  10. Lauren Sauer: Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  11. David L Thomas: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  12. Yukari C Manabe: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Abstract

BACKGROUND: Outpatient coronavirus disease 2019 (COVID-19) has been insufficiently characterized. To determine the progression of disease and determinants of hospitalization, we conducted a prospective cohort study.
METHODS: Outpatient adults with positive reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were recruited by phone between April 21 and July 23, 2020, after receiving outpatient or emergency department testing within a large health network in Maryland, United States. Symptoms were collected by participants on days 0, 3, 7, 14, 21, and 28, and portable pulse oximeter oxygen saturation (SaO), heart rate, and temperature were collected for 15 consecutive days. Baseline demographics, comorbid conditions, and vital signs were evaluated for risk of subsequent hospitalization using negative binomial and logistic regression.
RESULTS: Among 118 SARS-CoV-2-infected outpatients, the median age (interquartile range [IQR]) was 56.0 (50.0-63.0) years, and 50 (42.4%) were male. Among individuals in the first week of illness (n = 61), the most common symptoms included weakness/fatigue (65.7%), cough (58.8%), headache (45.6%), chills (38.2%), and anosmia (27.9%). Participants returned to their usual health a median (IQR) of 20 (13-38) days from symptom onset, and 66.0% of respondents were at their usual health during the fourth week of illness. Over 28 days, 10.9% presented to the emergency department and 7.6% required hospitalization. The area under the receiver operating characteristics curve for the initial home SaO for predicting subsequent hospitalization was 0.86 (95% CI, 0.73-0.99).
CONCLUSIONS: Symptoms often persisted but uncommonly progressed to hospitalization among outpatients with COVID-19. Home SaO may be a helpful tool to stratify risk of hospitalization.

Keywords

References

  1. Clin Microbiol Infect. 2020 Nov;26(11):1448-1449 [PMID: 32712242]
  2. Am J Emerg Med. 2020 Oct;38(10):2243.e5-2243.e6 [PMID: 32471783]
  3. Acad Emerg Med. 2020 Aug;27(8):681-692 [PMID: 32779828]
  4. N Engl J Med. 2020 Apr 30;382(18):1708-1720 [PMID: 32109013]
  5. Nature. 2020 Aug;584(7820):170 [PMID: 32782377]
  6. JAMA. 2020 Aug 11;324(6):603-605 [PMID: 32644129]
  7. Crit Care. 2020 Jun 8;24(1):313 [PMID: 32513249]
  8. Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21011-21013 [PMID: 32788355]
  9. Public Health. 2001 May;115(3):201-7 [PMID: 11429716]
  10. Am J Respir Crit Care Med. 2020 Aug 1;202(3):356-360 [PMID: 32539537]
  11. Value Health. 2020 Feb;23(2):227-235 [PMID: 32113628]
  12. J Biomed Inform. 2019 Jul;95:103208 [PMID: 31078660]
  13. J Med Virol. 2020 Oct;92(10):1902-1914 [PMID: 32293716]
  14. Ann Intern Med. 2021 Jan;174(1):33-41 [PMID: 32960645]
  15. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346 [PMID: 32214079]
  16. BMC Infect Dis. 2016 Jan 05;16:1 [PMID: 26729246]
  17. MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):841-846 [PMID: 32614810]
  18. BMC Infect Dis. 2018 Jul 28;18(1):353 [PMID: 30055573]
  19. Value Health. 2018 Feb;21(2):210-218 [PMID: 29477403]
  20. Open Forum Infect Dis. 2020 Dec 30;8(2):ofaa648 [PMID: 33604399]
  21. BMJ. 2020 Aug 13;370:m3218 [PMID: 32816748]
  22. JAMA Intern Med. 2020 Jul 21;: [PMID: 32692365]
  23. J Infect Dis. 2021 Jan 4;223(1):38-46 [PMID: 33098643]
  24. Lancet. 2020 Feb 15;395(10223):497-506 [PMID: 31986264]
  25. Mil Med. 2017 Sep;182(9):e1917-e1921 [PMID: 28885955]
  26. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998 [PMID: 32730238]

Grants

  1. K08 AI143391/NIAID NIH HHS
  2. U54 EB007958/NIBIB NIH HHS
  3. U54 HL143541/NHLBI NIH HHS
  4. UM1 AI068613/NIAID NIH HHS

Word Cloud

Created with Highcharts 10.0.0hospitalization0daysOutpatientcoronavirusCOVID-19healthSaOdisease21emergencydepartmentSymptomscollected728risksubsequentAmongoutpatientsmedian50weekillness6%9%usualBACKGROUND:2019insufficientlycharacterizeddetermineprogressiondeterminantsconductedprospectivecohortstudyMETHODS:adultspositivereversetranscriptionpolymerasechainreactionresultssevereacuterespiratorysyndrome2SARS-CoV-2recruitedphoneAprilJuly232020receivingoutpatienttestingwithinlargenetworkMarylandUnitedStatesparticipants314portablepulseoximeteroxygensaturationheartratetemperature15consecutiveBaselinedemographicscomorbidconditionsvitalsignsevaluatedusingnegativebinomiallogisticregressionRESULTS:118SARS-CoV-2-infectedageinterquartilerange[IQR]560-63years424%maleindividualsfirstn = 61commonsymptomsincludedweakness/fatigue657%cough588%headache45chills382%anosmia27ParticipantsreturnedIQR2013-38symptomonset660%respondentsfourth10presentedrequiredareareceiveroperatingcharacteristicscurveinitialhomepredicting8695%CI73-099CONCLUSIONS:oftenpersisteduncommonlyprogressedamongHomemayhelpfultoolstratifyClinicalCourseSetting:ProspectiveCohortStudyambulatorycareinfections/epidemiologymiddleagedrecoveryfunctiontreatmentoutcome

Similar Articles

Cited By